


INTERIM REPORT AS OF MARCH 31, 2010



## PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

# CONTENTS

FOREWORD BY THE BOARD OF MANAGEMENT .....	3
INTERIM GROUP MANAGEMENT REPORT .....	5
CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2010 .....	9
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME .....	11
for the Period from January 1 to March 31, 2010	
CONSOLIDATED CASH FLOW STATEMENT .....	12
for the Period from January 1 to March 31, 2010	
STATEMENT OF CHANGES IN GROUP SHAREHOLDERS' EQUITY .....	13
for the Period from January 1 to March 31, 2010	
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS .....	15
for the Period from January 1 to March 31, 2010	
SERVICE .....	18

## FOREWORD BY THE BOARD OF MANAGEMENT

### Dear Shareholders,

Upon the publication of our 2009 Annual Report two weeks ago we could report that the past financial year was the best in our company's history. In 2009, we not only substantially expanded our production activities, achieving marked growth in sales and earnings as a result, but also significantly boosted our development activities. Last year, we took the next steps towards generating further substantial growth at the STRATEC Group, thus laying foundations for a further year of strong growth in 2010.

Following the marked growth in sales and earnings in the first quarter, the 2010 financial year will continue to be characterized by the pending market launches by our customers of four new analyzer systems. For two of these analyzer systems, the ramp-up phase in preparation for serial production had already been completed by the end of the first quarter of 2010. We have now launched serial production on these systems and begun to deliver them to our customers for initial stocking. In the next stage, the respective customers will start marketing these analyzer systems. For the other two analyzer systems, our customers expect serial production to begin in the second half of 2010.

Right now, we are significantly expanding our production and development capacities to enable us to handle ongoing strong turnover with analyzer systems already established on the market, as well as the increasing number of pre-serial and serial systems to be manufactured, while also doing justice to the development orders currently in the negotiation stage.

Work therefore began in the first quarter of 2010 on the construction of a new building at our Birkenfeld location. This building, with floor space of 5,000 m<sup>2</sup>, is due to be completed in November 2010. Soon, it will be possible to track the construction progress on a webcam available at our homepage at [www.stratec-biomedical.de](http://www.stratec-biomedical.de). Work on the new building in Switzerland already began in the 2009 financial year. The move into the new production building, which has a floor surface of 4,000 m<sup>2</sup>, is scheduled for June 2010. These measures will virtually double our production capacities.

Our business results for the first three months of the current year confirm the increase in sales to between € 96 million and € 102 million announced by the company. Our forecast is backed up by extremely positive expectations communicated by our customers concerning the turnover in their system solutions. The substantial increase in demand for individual analyzer systems from our customers led to an unprecedented order backlog at our company at the end of the first quarter of 2010, one which we intend to gradually work down over the coming quarters.

Sales in the first three months of the 2010 financial year (January 1, 2010 to March 31, 2010) showed significant growth of 20.8% to € 20.2 million (Q1/2009: € 16.7 million). They were accompanied by EBIT of € 3.7 million (Q1/2009: € 2.7 million), equivalent to a 36.7% increase. The EBIT margin amounted to 18.5% in the first quarter of 2010 (Q1 /2009: 16.4%) and is thus developing on schedule to reach the target of at least 19.0% forecast by the company for the 2010 financial year as a whole. Four major development programs, benefits of scale in production and the increasing share of sales generated with consumables and spare parts should facilitate further growth in the EBIT margin.


In view of the company's expected future business performance and given its high volume of liquidity and high equity ratio, the Supervisory Board and Board of Management will be proposing the distribution to shareholders of a dividend of € 0.45 per share with dividend entitlement (previous year: € 0.35) for approval at the Annual General Meeting on May 21, 2010. Subject to approval by the Annual General Meeting, this would correspond to a total distribution of € 5.1 million (previous year: € 4.0 million). We would be pleased to welcome you to our Annual General Meeting, due to be held in Pforzheim on Friday, May 21, 2010.

Birkenfeld, April 2010

The Board of Management of  
STRATEC Biomedical Systems AG



Hermann Leistner



Marcus Wolfinger



Bernd M. Steidle

# INTERIM GROUP MANAGEMENT REPORT

## REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

While sales rose by 20.8% from € 16.7 million in the previous year to € 20.2 million in the first three months of the 2010 financial year, the Group increased its overall performance in the same period by 21.8% from € 19.1 million to € 23.2 million. In line with these developments, the cost of materials grew from € 9.8 million to € 11.5 million.

Due in particular to the increase in development activities, as well as to the further expansion in production capacities and the acquisition of Invitek in April of the previous year, personnel expenses rose from € 4.5 million to € 5.6 million. Although Invitek is not included in the figures for the first quarter of the previous year (initial consolidation: 4 / 2009), other operating expenses only rose minimally by € 0.1 million to € 1.8 million. Depreciation and amortization increased to € 0.7 million. STRATEC thus generated consolidated net income of € 2.9 million in the period under report (previous year: € 2.2 million), corresponding to earnings per share of € 0.25 (previous year: € 0.19).

In the balance sheet, the forthcoming launch of serial production on two development projects led inventories to rise from € 31.6 million to € 37.2 million. Total receivables and other assets increased by € 4.1 million to € 20.6 million, while cash and cash equivalents decreased from € 21.2 million to € 17.4 million in the period under report.

The equity ratio decreased from 69.1% to 67.5%. The increase in non-current financial liabilities is to be viewed in connection with the taking up of a loan for the construction of a production building at Robion AG. The increase in trade payables was due to increased procurement volumes for raw materials and supplies.

With an outflow of funds of € 1.3 million, the Group's investment activities in the first three months of the 2010 financial year were characterized by the construction progress on the production building at Robion AG. Moreover, over the same period the STRATEC Group invested € 0.5 million (previous year: € 0.6 million) in property, plant and equipment, especially tools, and € 0.1 million (previous year: € 0.1 million) in intangible assets.

## CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

According to an assessment published by the International Monetary Fund (IMF) on April 21, 2010, robust growth in most emerging and developing economies means that the global economy is set to grow faster than previously assumed. The IMF has therefore raised its forecast for 2010, already corrected upwards to 3.9% in January 2010, once more to 4.3%. While the economic growth expected in euro area countries remains unchanged at 1% due to the potential escalation in the debt crisis in individual member countries, the USA are expected to achieve substantially higher growth of 3.1% in 2010.

Irrespective of this, global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21<sup>st</sup> century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of medical tests to be performed, but will also result in new, unique opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks, such as the recent recession, only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers and the fact that the work performed is invoiced almost exclusively in euros further minimize the implications of the crisis for STRATEC.

## REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

On December 17, 2009, STRATEC published a forecast of the Group's further sales and earnings performance.

STRATEC expects to generate sales in a range of €96 million to €102 million in the 2010 financial year. Four major development programs, benefits of scale in production and the increasing share of sales generated with consumables and spare parts will facilitate further growth in the EBIT margin. STRATEC expects its EBIT margin for 2010 to rise by at least 0.5 percentage points to at least 19.0%.

The marked increase in the "inventories" balance sheet item, which is due to the pending launch of serial production on two development projects, will return to a lower level once again following the launch of marketing by our customers for the analyzer systems involved in the development projects.

In view of the stable growth in all projects and the prospects and customers forecasts received for new programs, STRATEC expects to generate continuous growth in the coming years. The average rate of growth in sales (CAGR) between 2010 and 2012 is thus expected to exceed 15% a year.

Furthermore, we are holding talks on promising projects with existing and potential customers, which lead us to expect further growth driven by new projects well beyond 2012.

Following the international economic crisis and the resultant economic downturn, the macroeconomic climate has begun to improve once again. All industrial sectors are nevertheless still confronted with a low level of budgeting reliability. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.



We avert potential receivables default risk by working with trade credit insurance policies. In view of our existing development projects and forecasts, as well as the partial conversion of our forecast systems to the dates at which orders are actually placed by STRATEC's customers, however, our degree of forecasting reliability remains very high.

Apart from this, since the assessment of the situation of the company provided on March 19, 2010, upon the compilation of the Annual Report for the 2009 financial year, no new information has arisen which could lead to any change in our assessment of the expected development of the company.

## OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2009 financial year dated March 19, 2010. Reference is made to the "Risk Report" section within the 2009 Group Management Report for details concerning our risk management system and our company's specific opportunity and risk profile.

# CONSOLIDATED BALANCE SHEET

as of March 31, 2010

of STRATEC Biomedical Systems AG

ASSETS in € thousand	03.31.2010	12.31.2009
<b>NON-CURRENT ASSETS</b>		
Goodwill .....	2,139	2,141
Other intangible assets .....	4,265	4,385
Property, plant and equipment .....	9,929	8,890
Interests in associates .....	311	310
Deferred tax assets .....	125	125
	<b>16,769</b>	<b>15,851</b>
<b>CURRENT ASSETS</b>		
Raw materials and supplies .....	9,322	6,915
Unfinished products, unfinished services .....	26,715	23,893
Finished products and goods .....	905	606
Prepayments made .....	232	223
Trade receivables .....	12,896	9,914
Future receivables from construction contracts .....	4,978	4,922
Receivables from associates .....	355	165
Other receivables and other assets .....	2,375	1,456
Securities .....	698	654
Cash and cash equivalents .....	17,362	21,186
	<b>75,838</b>	<b>69,934</b>
<b>TOTAL ASSETS</b>	<b>92,607</b>	<b>85,785</b>

SHAREHOLDERS' EQUITY AND DEBT in € thousand	03.31.2010	12.31.2009
<b>SHAREHOLDERS' EQUITY</b>		
Share capital .....	11,446	11,446
Capital reserve .....	11,223	11,167
Revenue reserves .....	38,106	26,433
Consolidated net income .....	2,873	11,674
Other equity .....	-1,164	-1,433
	<b>62,484</b>	<b>59,287</b>
<b>DEBT</b>		
<b>Non-current debt</b>		
Non-current financial liabilities .....	6,438	5,602
Pension provisions .....	105	105
Deferred taxes .....	1,679	1,637
	<b>8,222</b>	<b>7,344</b>
<b>Current debt</b>		
Current financial liabilities .....	481	488
Trade payables .....	5,150	3,421
Liabilities to associates .....	346	24
Other current liabilities .....	13,954	13,670
Current provisions .....	1,659	1,301
Income tax liabilities .....	311	250
	<b>21,901</b>	<b>19,154</b>
<b>Total shareholders' equity and debt</b>	<b>92,607</b>	<b>85,785</b>

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from January 1 to March 31, 2010  
of STRATEC Biomedical Systems AG

in € thousand	01.01.-03.31.2010	01.01.-03.31.2009
<b>Sales</b>	<b>20,225</b>	<b>16,743</b>
Increase in volume of finished and unfinished products and unfinished services	2,899	2,234
Other own work capitalized	105	91
<b>Overall performance</b>	<b>23,229</b>	<b>19,068</b>
Other operating income	148	156
Cost of raw materials and supplies	10,999	9,355
Cost of purchased services	518	413
Personnel expenses	5,625	4,462
Other operating expenses	1,802	1,669
<b>EBITDA</b>	<b>4,433</b>	<b>3,325</b>
Amortization of intangible assets and depreciation of property, plant and equipment	690	587
<b>EBIT</b>	<b>3,743</b>	<b>2,738</b>
Net financial expenses	3	193
<b>Operating result (EBT)</b>	<b>3,746</b>	<b>2,931</b>
Current tax expenses	851	778
Deferred tax expenses (previous year: tax income)	22	22
<b>Consolidated net income</b>	<b>2,873</b>	<b>2,175</b>
<b>Earnings per share in €</b>	<b>0.25</b>	<b>0.19</b>
Number of shares used as basis	11,381,841	11,359,898
<b>Earnings per share, diluted, in €</b>	<b>0.25</b>	<b>0.19</b>
Number of shares used as basis, diluted	11,522,171	11,387,716

# CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to March 31, 2010  
of STRATEC Biomedical Systems AG

in € thousand	01.01.-03.31.2010	01.01.-03.31.2009
Consolidated net income	2,873	2,175
Depreciation and amortization	690	587
Current income tax expenses	851	778
Income taxes paid less income taxes received	-793	-1,416
Financial income	-60	-60
Financial expenses	58	55
Interest paid	-58	-55
Interest received	3	60
Other non-cash expenses	136	57
Other non-cash income	-74	-43
<b>Cash flow</b>	<b>3,626</b>	<b>2,138</b>
Change in deferred taxes through profit or loss	21	-22
Profit on disposals of non-current assets	0	-188
Increase in inventories, trade receivables and other assets	-9,531	-3,735
Increase in trade payables and other liabilities	2,460	1,088
<b>Outflow of funds from operating activities</b>	<b>-3,424</b>	<b>-719</b>
Incoming payments from disposals of non-current assets		
Property, plant and equipment	0	0
Financial assets	0	799
Outgoing payments for investments in consolidated non-current assets		
Intangible assets	-84	-78
Property, plant and equipment	-456	-594
Prepayments made / assets under construction	-786	0
Financial assets	0	0
<b>Outflow of funds for investment activities (previous year: inflow)</b>	<b>-1,326</b>	<b>127</b>
Incoming payments from taking up of financial liabilities	1,020	0
Outgoing payments for repayment of financial liabilities	-222	-226
Incoming payments from issues of shares for employee stock option programs	0	0
<b>Inflow of funds for financing activities (previous year: outflow)</b>	<b>798</b>	<b>-226</b>
<b>Cash-effective change in cash and cash equivalents</b>	<b>-3,952</b>	<b>-818</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>21,187</b>	<b>19,208</b>
Change in cash and cash equivalents due to changes in exchange rates	127	-54
<b>Cash and cash equivalents at end of period</b>	<b>17,362</b>	<b>18,336</b>

# STATEMENT OF CHANGES IN GROUP SHAREHOLDERS' EQUITY

for the Period from January 1 to March 31, 2010  
of STRATEC Biomedical Systems AG

## JANUARY - MARCH 2009

in € thousand	Share capital	Capital reserve	Revenue reserves	
			Retained earnings	Other revenue reserves
<b>Balance at 12.31.2008</b>	<b>11,426</b>	<b>10,746</b>	<b>18,741</b>	<b>5,539</b>
Dividend payment				
Allocation to other revenue reserves				2,000
Profit carried forward			4,131	
Issue of subscription shares from stock option programs	0	0		
Allocations due to stock option programs		54		
Currency translation				
Consolidated net income				
<b>Balance at 03.31.2009</b>	<b>11,426</b>	<b>10,800</b>	<b>22,872</b>	<b>7,539</b>

## JANUARY- MARCH 2010

in € thousand	Share capital	Capital reserve	Revenue reserves	
			Retained earnings	Other revenue reserves
<b>Balance at 12.31.2009</b>	<b>11,446</b>	<b>11,167</b>	<b>18,893</b>	<b>7,540</b>
Dividend payment				
Allocation to other revenue reserves				3,000
Profit carried forward			8,674	
Issue of subscription shares from stock option programs	0	0		
Allocations due to stock option plans		56		
Consolidated net income				
<b>Balance at 03.31.2010</b>	<b>11,446</b>	<b>11,223</b>	<b>27,567</b>	<b>10,540</b>

	Consolidated net income	Other equity			Group equity
		Fair value reserve	Treasury stock	Currency translation	
	6,131	0	-2,014	-667	49,902
	0				0
	-2,000				0
	-4,131				0
					0
					54
				-77	-77
	2,175				2,175
	<b>2,175</b>	<b>0</b>	<b>-2,014</b>	<b>-744</b>	<b>52,054</b>

	Consolidated net income	Other equity			Group equity
		Fair value reserve	Treasury stock	Currency translation	
	11,674	0	-998	-435	59,287
	0				0
	-3,000				0
	-8,674				0
					0
					56
	2,872			269	3,141
	<b>2,872</b>	<b>0</b>	<b>-998</b>	<b>-166</b>	<b>62,484</b>

# NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

for the Period from January 1 to March 31, 2010  
of STRATEC Biomedical Systems AG

## Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC AG as of December 31, 2009, were compiled in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of March 31, 2010, which has been compiled on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2009 financial year. Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of March 31, 2010. Moreover, when compiling the interim report, account was also taken of the near-final draft of German Accounting Standard No. 16 (DRS 16) – Interim Reporting – of the German Accounting Standards Committee (DRSC e.V).

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, Wirtschaftstreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC AG as of December 31, 2009 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€ thousand).

## Breakdown of sales at the Group

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousand	Germany	EU	Other	Total
January - March 2010	2,647	13,900	3,678	20,225
	13.1%	68.7%	18.2%	100.0%

in € thousand	Germany	EU	Other	Total
January - March 2009	4,094	10,439	2,210	16,743
	24.5%	62.3%	13.2%	100.0%



## Research and development expenses

The expenses relating to research and project management, and to development services not fulfilling the capitalization criteria set out in IAS 38, amounted to € 1.5 million in the first three months of the 2010 financial year (previous year: € 1.3 million). These have been reported, mainly as personnel expenses, in the company's consolidated statement of comprehensive income. Moreover, procurement volumes of around € 0.3 million (previous year: € 0.2 million) were incurred during the period under report in connection with materials used in research and development. These have been included in the cost of materials item.

## Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the statement of changes in group shareholders' equity on Pages 13 and 14.

The number of ordinary shares with a nominal value of € 1.00 each issued by STRATEC AG as of March 31, 2010, amounts to 11,445,736. These are all bearer shares.

## Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to Section 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC AG owned a total of 63,895 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of € 63,895.00 of the company's share capital and to a 0.56 % share of its equity.

In view of the several "conditional capitals" created by resolutions adopted at the Annual General Meetings held on May 28, 2003, June 23, 2006, May 16, 2007, and May 20, 2009, these various items have been combined below in the interests of clarity.

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

Conditional capital I / II / III / V	Board of Management / Managing Directors	Employees	Total
<b>Outstanding on 12.31.2009</b>	<b>265,000</b>	<b>44,130</b>	<b>309,130</b>
Issued .....	0	1,300	1,300
Exercised .....	0	0	0
Lapsed .....	0	0	0
<b>Outstanding on 03.31.2010</b>	<b>265,000</b>	<b>45,430</b>	<b>310,430</b>

**Employees**

Including temporary employees and employees at Invitek, which was acquired in April 2009, the STRATEC Group had a total workforce of 387 employees as of March 31, 2010 (previous year: 299).

**Major events after the interim reporting date**

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

**Responsibility statement**

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group for the remaining months of the financial year.

# SERVICE

## FINANCIAL CALENDAR

- April 28, 2010** ..... Interim report as of March 31, 2010
- May 21, 2010** ..... Annual General Meeting, Pforzheim, Germany
- July 28, 2010** ..... Interim report as of June 30, 2010
- October 27, 2010** ..... Interim report as of September 30, 2010
- November 2010** ..... Deutsches Eigenkapitalforum, Frankfurt am Main, Germany  
– Analysts' conference –

Furthermore, based on current planning, STRATEC will also be taking part in the following capital market conferences in 2010:

- May 2010** Goldman Sachs European Small and Mid-Cap Symposium, London, UK  
Morgan Stanley European Medtech Conference, London, UK  
7<sup>th</sup> Annual Bank of America Merrill Lynch Biotech Medtech and Mid-cap Pharma one-on-one Conference, London, UK
- June 2010** Jefferies 2010 Global Life Sciences Conference, New York, USA  
Goldman Sachs 31<sup>st</sup> Annual Global Healthcare Conference, Los Angeles, USA  
Piper Jaffray Europe Conference, London, UK
- August 2010** Commerzbank Conference Life Sciences, Frankfurt am Main, Germany
- September 2010** DZ Bank German Healthcare Conference, Zurich, Switzerland  
UBS Global Life Sciences Conference, New York, USA
- October 2010** Jefferies Global SpecPharma & European Healthcare Conference, London, UK
- November 2010** WestLB Deutschland Conference, Frankfurt am Main, Germany

Partially incomplete / subject to amendment

## ABOUT STRATEC

STRATEC Biomedical Systems AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

Further information about STRATEC is available on the internet at [www.stratec-biomedical.de](http://www.stratec-biomedical.de).

## IMPRINT

### **PUBLISHED BY**

STRATEC Biomedical Systems AG  
Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0  
Fax: +49 7082 7916-999  
[info@stratec-biomedical.de](mailto:info@stratec-biomedical.de)  
[www.stratec-biomedical.de](http://www.stratec-biomedical.de)

### **Investor Relations**

ANDREAS KÜNZEL  
Phone: +49 7082 7916-185  
Fax: +49 7082 7916-999  
[a.kuenzel@stratec-biomedical.de](mailto:a.kuenzel@stratec-biomedical.de)

ANDRE LOY  
Phone: +49 7082 7916-190  
Fax: +49 7082 7916-999  
[a.loy@stratec-biomedical.de](mailto:a.loy@stratec-biomedical.de)

## NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

**STRATEC BIOMEDICAL SYSTEMS AG**

Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

[info@stratec-biomedical.de](mailto:info@stratec-biomedical.de)

[www.stratec-biomedical.de](http://www.stratec-biomedical.de)